[{"data":1,"prerenderedAt":286},["ShallowReactive",2],{"story-115984-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":47,"questions":48,"relatedArticles":73,"body_color":284,"card_color":285},"115984",null,"Biotech Boom Signals Healthcare Product Opportunity | E-Commerce Sellers' Guide to Medical Device Distribution Expansion","- ImmunityBio's $113M ANKTIVA revenue surge across 33 countries reveals emerging healthcare marketplace opportunities for sellers in medical supplies, wellness products, and patient support categories",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,16],"https://media.inshorts.com/inshorts/images/v1/variants/jpg/m/2026/02_feb/19_thu/img_1771513665675_979.jpg","https://s.yimg.com/ny/api/res/1.2/9nZdnerF8ZN_1DaybpBa6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQzOA--/https://media.zenfs.com/en/motleyfool.com/acf9611c947ed2a9982233c610f2abcb","https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg","https://menafn.com/updates/pr/2026-02/19/AN_web-p_adeb4image_story.webp","https://s.yimg.com/ny/api/res/1.2/NHPVCzN74RcEZvli64RUOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNw--/https://media.zenfs.com/en/zacks.com/0abdcee17aba3223065f252e14650089","https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_4.jpg?width=1200&height=800&fit=crop","https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","https://news.stocktwits-cdn.com/large_patrick_soon_shiong_jpg_5f4d6bc18d.webp","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://media.kare11.com/assets/AssociatedPress/images/f42a6d9e-fc59-4f15-833c-a3c834309bc5/20260223T144510/f42a6d9e-fc59-4f15-833c-a3c834309bc5_1140x641.png","https://cdn.benzinga.com/files/images/story/2026/02/23/A-Detailed-Stock-Market-Data-Display-Wit.jpeg?width=1200&height=800&fit=crop","https://oncodaily.com/pub/uploads/2026/01/Pat-Soon-Shiong.jpg-1.webp","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F857501%2Fgettyimages-1464232456-4.jpg&w=3840&op=resize","https://content.timothysykes.com/cdn-cgi/image/quality=90,format=webp,width=740/https://content.timothysykes.com/wp-content/uploads/2026/02/immunitybios-anktiva-sexpanding-market-reachs-in-europe-saudi-arabia.png","https://images.unsplash.com/photo-1563233269-7e86880558a7?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3wyNzUwNjN8MHwxfHNlYXJjaHwyNnx8Y2FuY2VyfGVufDB8fHx8MTc3MTg0MzAzMHww&ixlib=rb-4.1.0&q=80&w=1080","https://www.biospectrumasia.com/uploads/articles/screenshot_20_2_2026_191232_wamanhongkong_com-27226.jpeg","https://res.cloudinary.com/tikr/images/f_auto,q_auto,w_800/v1771479866/images/IBRX-stock-2/IBRX-stock-2","https://s.yimg.com/ny/api/res/1.2/FGKJ8quMN7J40ZUDMX3ZwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/motleyfool.com/4a6e22038293f72cc259a3c5887e53bd","https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg","https://nai500.com/wp-content/uploads/2025/03/approved.png","https://userupload.gurufocus.com/2026162561162059776.png","https://mdb.ad-hoc-news.de/bilder/bild-2476614_800_400.jpg","https://news.finterra.ai/wp-content/uploads/2026/02/241495b5-e5bf-4546-b5ee-d974f10f5c5c-1024x683.png","https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2Fdbf4812d84ab78c74b512c7cb2e4d70bee11215c-1401x1251.png%3Fw%3D1401%26h%3D1251&w=3840&op=resize","https://www.quiverquant.com/images/ibrx_rect_new.png","https://s.yimg.com/ny/api/res/1.2/PvYusB99D3ZEJVv6PtCz8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQwOA--/https://media.zenfs.com/en/simply_wall_st__316/9efb665d244f801cdee4b34b9843ed3f","https://media.wkyc.com/assets/AssociatedPress/images/f42a6d9e-fc59-4f15-833c-a3c834309bc5/20260223T144510/f42a6d9e-fc59-4f15-833c-a3c834309bc5_1140x641.png","https://s.yimg.com/ny/api/res/1.2/z1KZaSibgagcQ5R9A7sJBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/business-wire.com/4921919e072e7a238e96672db885c93e","https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2015/07/Dentist-Dental-Root-Canal-Operation-Healthcare-Health-Medicine-Drugs.jpg","https://s.yimg.com/ny/api/res/1.2/wDGi8BPKWSX0.zwU.6HAKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTUxOA--/https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a","https://news.stocktwits-cdn.com/large_immunitybio_jpg_eb6402d336.webp","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2023-12-28T084504Z_1_LYNXMPEJBR05W_RTROPTP_3_USA-STOCKS.JPG","https://content.stockstotrade.com/wp-content/uploads/2026/02/dynamic-stock-market-growth-20.png","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1WSGXF.img?w=768&h=512&m=6","https://s.yimg.com/ny/api/res/1.2/Tm9e55wRkEF7jlDJeIIUcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ0Mg--/https://media.zenfs.com/en/simply_wall_st__316/bd88ab849c43778ba40e0d13b9735f3a","https://news.stocktwits-cdn.com/large_immunitybio_stock_jpg_9eab8bde17.webp","https://mdb.ad-hoc-news.de/bilder/bild-2477013_800_400.jpg","**ImmunityBio's exceptional 700% year-over-year revenue growth for ANKTIVA ($113M in 2025 net product revenue) and rapid global expansion across 33 countries signals a transformative moment in healthcare product commercialization that creates indirect but significant opportunities for cross-border e-commerce sellers.** The company's strategic expansion—including partnerships with Accord Healthcare across 30 European countries, BioPharma Cigalah for MENA region coverage, and regulatory approvals in the US, EU, UK, and Saudi Arabia—demonstrates how specialized medical products achieve rapid market penetration when backed by strong clinical data and distributed infrastructure.\n\n**For e-commerce sellers, this biotech success story reveals three critical market dynamics:** First, the 750% increase in unit sales volume (not just revenue) indicates genuine clinical adoption and patient demand, not just price inflation. This validates that healthcare product categories are experiencing sustained growth beyond temporary pandemic-driven spikes. Second, ImmunityBio's multi-jurisdictional approval strategy (FDA approval April 2024, Saudi Arabia lung cancer approval January 2026) shows how regulatory pathways create predictable commercial windows—a model e-commerce sellers can monitor for complementary product opportunities. Third, the company's 80.41% gross margin despite deep operational losses demonstrates that healthcare products command premium pricing structures, suggesting high-margin opportunities for sellers in supportive care categories (patient comfort items, medical supplies, wellness supplements) that complement pharmaceutical treatments.\n\n**The operational expansion model is particularly instructive for sellers:** ImmunityBio deployed over 100 sales and medical professionals across 30 European countries and established regional subsidiaries in Dublin and Saudi Arabia. This infrastructure-heavy approach contrasts with pure e-commerce models but reveals where sellers can differentiate. E-commerce sellers can capture demand in adjacent categories—medical-grade compression garments, specialized nutrition for cancer patients, post-treatment wellness products, and clinical trial support supplies—where direct-to-consumer distribution through Amazon, eBay, and Shopify provides advantages over traditional pharmaceutical channels. The company's 20% quarter-over-quarter growth in Q4 2025 indicates sustained momentum, suggesting these complementary categories will experience corresponding demand increases through 2026.\n\n**Market timing is critical:** With 30+ active clinical trials spanning 10 tumor types and planned regulatory submissions for 2026, ANKTIVA's label expansion into glioblastoma, pancreatic cancer, and lymphopenia treatment will create successive waves of patient populations seeking supportive care products. Sellers should monitor FDA approval announcements and clinical trial enrollment data to anticipate demand spikes 3-6 months before commercial launches. The company's patent protection through 2035 (US Patents 9,925,247 and 11,071,774) ensures long-term market stability, reducing risk of generic competition that could destabilize pricing in complementary product categories.",[49,52,55,58,61,64,67,70],{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"When should sellers launch products to align with ANKTIVA's clinical trial timeline?","ImmunityBio has 30+ active clinical trials with planned FDA submissions in 2026 for glioblastoma, pancreatic cancer, and lymphopenia treatment. Historical patterns show patient demand peaks 2-4 months after regulatory approval announcements. Sellers should: (1) Set up Google Alerts for 'ANKTIVA FDA approval' and 'ImmunityBio clinical trial results'; (2) Launch complementary products 90 days before anticipated approvals; (3) Prepare inventory for Q2-Q3 2026 when new indications likely receive approval; (4) Monitor clinical trial enrollment sites (clinicaltrials.gov) to identify patient populations and geographic demand centers. The company's 20% quarter-over-quarter growth in Q4 2025 indicates sustained momentum, so early positioning in 2026 will capture first-mover advantage in emerging patient segments.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"How does ImmunityBio's multi-country approval strategy affect e-commerce seller compliance requirements?","ImmunityBio's expansion across 33 countries (US, EU, UK, Saudi Arabia) demonstrates that healthcare product distribution requires jurisdiction-specific compliance. For e-commerce sellers, this means: (1) EU sellers must comply with medical device classification rules (Class I-IV) and CE marking requirements; (2) UK sellers post-Brexit need separate MHRA registration; (3) Saudi Arabia and MENA region sales require local partnership or subsidiary registration. The company's partnerships with Accord Healthcare (Europe) and BioPharma Cigalah (MENA) show that regional distribution partners are essential. Sellers should verify product classification in each target market before listing—misclassification can result in €50K+ fines. Use Amazon's compliance tools and consult regulatory experts for medical device categorization.",{"title":56,"answer":57,"author":5,"avatar":5,"time":5},"How does ImmunityBio's patent protection through 2035 affect seller competition and pricing?","ImmunityBio's patents (US 9,925,247 and 11,071,774) protect ANKTIVA combinations with checkpoint inhibitors through 2035, ensuring long-term market exclusivity. For e-commerce sellers, this creates a stable market environment for complementary products—generic competition won't destabilize pricing in supportive care categories for 9+ years. This stability allows sellers to: (1) Invest in brand building and customer loyalty without fear of sudden price wars; (2) Develop specialized product lines targeting specific patient populations; (3) Build supplier relationships with confidence in sustained demand. However, sellers should avoid direct competition with ANKTIVA or checkpoint inhibitor combinations, which remain prescription-only. Focus instead on over-the-counter supportive care, wellness, and patient education products where patent protection doesn't apply.",{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"What gross margin expectations should sellers have for healthcare product categories?","ImmunityBio maintains 80.41% gross margin despite deep operational losses, indicating healthcare products command premium pricing. For e-commerce sellers, this translates to realistic margin expectations: medical-grade wellness products typically achieve 50-65% gross margins (vs. 30-40% for standard consumer goods), after accounting for higher COGS, regulatory compliance costs, and specialized packaging. Sellers should expect: (1) 15-25% higher product costs for medical-grade certification; (2) 10-15% additional compliance and documentation expenses; (3) 5-10% premium pricing justified by clinical positioning. However, volume growth is critical—ImmunityBio's 750% unit sales increase shows that scale drives profitability despite high operational costs. Sellers should prioritize volume growth in 2026 to achieve similar margin expansion.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"What inventory and supply chain adjustments should sellers make for MENA market entry?","ImmunityBio's Saudi Arabia subsidiary launch (60-day commercial timeline from January 2026 approval) signals rapid MENA market expansion. Sellers should prepare 90-120 day inventory buffers for Saudi Arabia and UAE Amazon marketplaces, as shipping times from US/EU suppliers average 30-45 days. Establish relationships with local 3PL providers in Dubai and Riyadh to reduce fulfillment costs (FBA shipping to MENA costs 15-25% more than US). Verify product compliance with Saudi Food and Drug Authority (SFDA) and UAE Ministry of Health requirements—allocate $3,000-8,000 for regulatory documentation. Consider pre-positioning inventory in EU warehouses (Dublin, where ImmunityBio established operations) to serve both EU and MENA markets efficiently. Monitor currency fluctuations (SAR/AED stability) and adjust pricing quarterly to maintain 60-70% gross margins.",{"title":65,"answer":66,"author":5,"avatar":5,"time":5},"What regional expansion opportunities exist for sellers in MENA and European markets?","ImmunityBio's partnerships with Accord Healthcare (30 European countries) and BioPharma Cigalah (MENA region) signal strong market demand in these regions. For sellers: (1) European opportunity—Accord Healthcare's deployment of 100+ sales professionals across 30 countries indicates robust healthcare infrastructure and patient access. Sellers should prioritize EU/UK listings for medical-grade wellness products, targeting countries with highest cancer incidence (Germany, France, Italy, Spain). (2) MENA opportunity—Saudi Arabia's January 2026 approval for lung cancer indication and planned 60-day commercial launch shows rapid market development. Sellers should establish Saudi Arabia and UAE marketplace presence (Amazon.sa, Noon.com) for patient support products, leveraging the region's high healthcare spending. Both regions offer 20-30% higher margins than US markets due to limited competition and premium positioning of healthcare products.",{"title":68,"answer":69,"author":5,"avatar":5,"time":5},"What product categories benefit most from biotech company expansion like ImmunityBio's?","Cancer immunotherapy expansion drives demand in four primary categories: (1) Patient comfort items—specialized pillows, compression sleeves, and recovery garments; (2) Nutritional support—medical-grade supplements addressing chemotherapy-induced nausea and lymphopenia; (3) Wellness and recovery—post-treatment skincare, hair recovery products, and stress management tools; (4) Clinical trial support—patient education materials, appointment tracking tools, and symptom management apps. ImmunityBio's 750% unit sales increase indicates sustained patient demand, not temporary spikes. Sellers with existing health/wellness inventory can expand into medical-grade variants targeting cancer patient demographics, which command 15-25% price premiums over standard wellness products.",{"title":71,"answer":72,"author":5,"avatar":5,"time":5},"How can e-commerce sellers capitalize on ImmunityBio's ANKTIVA expansion into 33 countries?","ImmunityBio's 700% revenue growth and regulatory approvals across US, EU, UK, and Saudi Arabia create demand for complementary healthcare products. Sellers should focus on patient support categories: medical-grade compression garments for cancer patients, specialized nutrition supplements for immunotherapy side effects, post-treatment wellness products, and clinical trial support supplies. Monitor FDA approval announcements and clinical trial enrollment data (30+ active trials across 10 tumor types) to anticipate demand 3-6 months before commercial launches. Amazon Health & Wellness and specialty medical marketplaces offer direct-to-consumer channels where sellers can reach patients seeking supportive care products that pharmaceutical companies don't distribute.",[74,79,84,88,93,98,102,106,110,114,118,122,127,132,136,140,144,148,153,157,161,165,169,173,177,181,185,189,194,197,201,205,209,213,217,220,224,228,232,235,239,243,247,252,256,259,263,267,270,273,276,280],{"id":75,"title":76,"source":77,"logo":44,"time":78},471239,"ImmunityBio (IBRX) Is Up 29.0% After EU Clears First ANKTIVA+BCG Immunotherapy For NMIBC CIS","https://finance.yahoo.com/news/immunitybio-ibrx-29-0-eu-121440429.html","5D AGO",{"id":80,"title":81,"source":82,"logo":5,"time":83},471237,"New cancer drug ANKTIVA reaches Saudi patients within 60 days","https://www.stocktitan.net/news/IBRX/immunity-bio-partners-with-biopharma-and-cigalah-healthcare-to-g3spkb5fte91.html","4D AGO",{"id":85,"title":86,"source":87,"logo":12,"time":78},471238,"ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up","https://www.zacks.com/stock/news/2871809/immunitybio-wins-eu-nod-for-bladder-cancer-combo-therapy-stock-up",{"id":89,"title":90,"source":91,"logo":5,"time":92},471231,"ImmunityBio: Q4 Earnings Snapshot","https://www.barchart.com/story/news/364772/immunitybio-q4-earnings-snapshot","1D AGO",{"id":94,"title":95,"source":96,"logo":16,"time":97},471232,"A Look At ImmunityBio (IBRX) Valuation After New European Anktiva Approval And International Expansion","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/a-look-at-immunitybio-ibrx-valuation-after-new-european-ankt","2D AGO",{"id":99,"title":100,"source":101,"logo":14,"time":78},474541,"ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?","https://finance.yahoo.com/news/immunitybio-ibrx-moves-41-9-110300883.html",{"id":103,"title":104,"source":105,"logo":5,"time":92},471230,"ImmunityBio (IBRX) Stock: Q4 Earnings Beat as ANKTIVA Revenue Surges","https://parameter.io/immunitybio-ibrx-stock-q4-earnings-beat-as-anktiva-revenue-surges/",{"id":107,"title":108,"source":109,"logo":5,"time":83},471235,"ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bl","https://www.pharmiweb.com/press-release/2026-02-20/immunitybio-partners-with-biopharma-and-cigalah-healthcare-to-launch-anktiva-in-saudi-arabia-for-bl",{"id":111,"title":112,"source":113,"logo":25,"time":83},471236,"ImmunityBio to launch ANKTIVA® in Saudi Arabia for bladder and lung cancer treatment","https://www.biospectrumasia.com/news/25/27226/immunitybio-to-launch-anktiva-in-saudi-arabia-for-bladder-and-lung-cancer-treatment.html",{"id":115,"title":116,"source":117,"logo":5,"time":92},471233,"ImmunityBio Stock Sinks Despite Bold Global Expansion","https://www.tipranks.com/news/catalyst/immunitybio-stock-sinks-despite-bold-global-expansion",{"id":119,"title":120,"source":121,"logo":17,"time":83},471234,"IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug","https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-not-over-yet-chairman-says-trump-diplomacy-led-to-amazing-results-for-cancer-drug/cZRZDoZR4Dx",{"id":123,"title":124,"source":125,"logo":5,"time":126},474518,"ImmunityBio reports $113M in ANKTIVA sales, up 700% in 2025 By Investing.com","https://in.investing.com/news/company-news/immunitybio-reports-113m-in-anktiva-sales-up-700-in-2025-93CH-5251446","17H AGO",{"id":128,"title":129,"source":130,"logo":5,"time":131},474519,"ImmunityBio's Revenue Soars on Global Expansion of Cancer Therapy","https://www.ad-hoc-news.de/boerse/ueberblick/immunitybio-s-revenue-soars-on-global-expansion-of-cancer-therapy/68607029","19H AGO",{"id":133,"title":134,"source":135,"logo":26,"time":78},471242,"ImmunityBio Stock Soars 42% After New Anktiva Approvals. Here’s What’s Driving the Rally","https://www.tikr.com/blog/immunitybio-stock-soars-42-after-new-anktiva-approvals-heres-whats-driving-the-rally",{"id":137,"title":138,"source":139,"logo":13,"time":78},471243,"Immunitybio Announces Partnership To Expand Access To Anktiva Across 30 Countries","https://menafn.com/1110765397/Immunitybio-Announces-Partnership-To-Expand-Access-To-Anktiva-Across-30-Countries",{"id":141,"title":142,"source":143,"logo":38,"time":78},471240,"ImmunityBio (IBRX) Soars to New High on Anktiva Future Expansion","https://finviz.com/news/315381/immunitybio-ibrx-soars-to-new-high-on-anktiva-future-expansion",{"id":145,"title":146,"source":147,"logo":35,"time":78},471241,"ImmunityBio’s EU Anktiva Nod Sparks Questions On Valuation And Momentum","https://finance.yahoo.com/news/immunitybio-eu-anktiva-nod-sparks-111032001.html",{"id":149,"title":150,"source":151,"logo":5,"time":152},471246,"ImmunityBio's Short Interest Turns Bullish Ahead of EU Decision","https://intellectia.ai/news/stock/immunitybios-short-interest-turns-bullish-ahead-of-eu-decision","6D AGO",{"id":154,"title":155,"source":156,"logo":32,"time":78},471247,"ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA","https://markets.financialcontent.com/stocks/article/finterra-2026-2-19-immunitybio-ibrx-the-rise-of-immunotherapy-20-and-the-global-expansion-of-anktiva",{"id":158,"title":159,"source":160,"logo":29,"time":78},471244,"ImmunityBio Soars Over 40% as European Commission Approves Bladder Cancer Drug Anktiva","https://nai500.com/blog/2026/02/immunitybio-soars-over-40-as-european-commission-approves-bladder-cancer-drug-anktiva/",{"id":162,"title":163,"source":164,"logo":10,"time":78},471245,"ImmunityBio expands Anktiva access across 30 countries | Tap to know more | Inshorts","https://inshorts.com/en/news/immunitybio-expands-anktiva-access-across-30-countries-1771513711571",{"id":166,"title":167,"source":168,"logo":45,"time":92},471217,"IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough","https://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us",{"id":170,"title":171,"source":172,"logo":24,"time":92},471218,"ImmunityBio to Launch Oncology Drug Anktiva in Saudi Arabia","https://www.navlindaily.com/article/29617/immunitybio-to-launch-oncology-drug-anktiva-in-saudi-arabia",{"id":174,"title":175,"source":176,"logo":5,"time":92},471215,"Earnings Flash (IBRX) ImmunityBio Posts Q4 Net Loss $0.06 a Share, vs. FactSet Est of $0.09 Loss","https://www.marketscreener.com/news/earnings-flash-ibrx-immunitybio-posts-q4-net-loss-0-06-a-share-vs-factset-est-of-0-09-loss-ce7e5dd2de8ef125",{"id":178,"title":179,"source":180,"logo":37,"time":92},471216,"ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally","https://finance.yahoo.com/news/immunitybio-reports-700-over-revenue-120000845.html",{"id":182,"title":183,"source":184,"logo":18,"time":92},471219,"ImmunityBio, Inc. SEC 10-K Report","https://www.tradingview.com/news/tradingview:45a9e0b37a9bb:0-immunitybio-inc-sec-10-k-report/",{"id":186,"title":187,"source":188,"logo":43,"time":92},474521,"IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans, hints at cancer breakthrough","https://www.msn.com/en-us/health/medical/ibrx-stock-to-open-week-on-a-high-chairman-teases-anktiva-s-3-year-expansion-plans-hints-at-cancer-breakthrough/ar-AA1WSwZw",{"id":190,"title":191,"source":192,"logo":16,"time":193},474520,"Why ImmunityBio (IBRX) Is Up 65.3% After ANKTIVA’s European Approval And New Regional Partnerships","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/why-immunitybio-ibrx-is-up-653-after-anktivas-european-appro","23H AGO",{"id":195,"title":124,"source":196,"logo":5,"time":92},471213,"https://ca.investing.com/news/company-news/immunitybio-reports-113m-in-anktiva-sales-up-700-in-2025-93CH-4471493",{"id":198,"title":199,"source":200,"logo":40,"time":92},471214,"ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11%","https://stocktwits.com/news-articles/markets/equity/ibrx-stock-immunitybio-q4-revenue-anktiva-growth/cZRtp77R4yO",{"id":202,"title":203,"source":204,"logo":31,"time":92},471211,"ImmunityBio's Revenue Surge and Global Expansion Amid Persistent Losses","https://www.ad-hoc-news.de/boerse/news/ueberblick/immunitybio-s-revenue-surge-and-global-expansion-amid-persistent-losses/68606177",{"id":206,"title":207,"source":208,"logo":21,"time":97},471212,"Pat Soon-Shiong: Advancing Immunotherapy 2.0 as a Next-Generation Model for Global Cancer Care","https://oncodaily.com/voices/pat-soon-shiong-459331",{"id":210,"title":211,"source":212,"logo":41,"time":92},473490,"ImmunityBio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025","https://www.marketscreener.com/news/immunitybio-inc-reports-earnings-results-for-the-fourth-quarter-ended-december-31-2025-ce7e5dd2d18ff223",{"id":214,"title":215,"source":216,"logo":5,"time":78},473491,"in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch","https://www.businesswire.com/news/home/20260219914846/en/ImmunityBio-Expands-Access-to-ANKTIVA-in-EU-with-New-Distribution-Partnership-and-Opens-Irish-Subsidiary-to-Support-European-Launch",{"id":218,"title":90,"source":219,"logo":19,"time":92},471228,"https://www.kare11.com/article/syndication/associatedpress/immunitybio-q4-earnings-snapshot/616-dd910b23-4421-46e4-b3b7-8521913017a3",{"id":221,"title":222,"source":223,"logo":42,"time":92},471229,"ImmunityBio Surges as EU Greenlights Key Cancer Therapy","https://stockstotrade.com/news/immunitybio-inc-ibrx-news-2026_02_23/",{"id":225,"title":226,"source":227,"logo":28,"time":92},471226,"ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates","https://www.nasdaq.com/articles/immunitybio-ibrx-reports-q4-loss-beats-revenue-estimates",{"id":229,"title":230,"source":231,"logo":27,"time":92},471347,"Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%","https://finance.yahoo.com/news/stock-market-today-feb-23-220451880.html",{"id":233,"title":226,"source":234,"logo":39,"time":92},471227,"https://finance.yahoo.com/news/immunitybio-ibrx-reports-q4-loss-153504050.html",{"id":236,"title":237,"source":238,"logo":5,"time":92},471348,"ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded Anktiva® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally","https://immunitybio.com/immunitybio-reports-700-year-over-year-revenue-growth-expanded-anktiva-approvals-in-lung-cancer-and-global-commercial-partnerships-in-33-countries-with-label-expansion-plans-globally/",{"id":240,"title":241,"source":242,"logo":34,"time":92},471220,"IMMUNITYBIO ($IBRX) Releases Q4 2025 Earnings","https://www.quiverquant.com/news/IMMUNITYBIO+%28%24IBRX%29+Releases+Q4+2025+Earnings",{"id":244,"title":245,"source":246,"logo":15,"time":92},472232,"Earnings Breakdown: ImmunityBio Q4","https://www.benzinga.com/insights/earnings/26/02/50775380/earnings-breakdown-immunitybio-q4",{"id":248,"title":249,"source":250,"logo":30,"time":251},473487,"Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight","https://www.gurufocus.com/news/8644453/decoding-immunitybio-inc-ibrx-a-strategic-swot-insight","22H AGO",{"id":253,"title":254,"source":255,"logo":11,"time":92},471221,"Why ImmunityBio Stock Is Soaring Again Today","https://finance.yahoo.com/news/why-immunitybio-stock-soaring-again-180117657.html",{"id":257,"title":129,"source":258,"logo":46,"time":131},473486,"https://www.ad-hoc-news.de/boerse/news/ueberblick/immunitybio-s-revenue-soars-on-global-expansion-of-cancer-therapy/68607029",{"id":260,"title":261,"source":262,"logo":5,"time":92},471224,"ImmunityBio, Inc. (IBRX) Stock: Surges 15% as ANKTIVA Revenue Jumps 700% in 2025","https://coincentral.com/immunitybio-inc-ibrx-stock-surges-15-as-anktiva-revenue-jumps-700-in-2025/",{"id":264,"title":265,"source":266,"logo":23,"time":92},471225,"ImmunityBio Authorized to Roll Out ANKTIVA in Europe and Saudi Arabia","https://www.timothysykes.com/news/immunitybio-inc-ibrx-news-2026_02_23-2/",{"id":268,"title":230,"source":269,"logo":33,"time":92},473644,"https://www.fool.com/coverage/stock-market-today/2026/02/23/stock-market-today-feb-23-immunitybio-surges-after-anktiva-revenue-jumps-700/",{"id":271,"title":254,"source":272,"logo":22,"time":92},471222,"https://www.fool.com/investing/2026/02/23/why-immunitybio-stock-is-soaring-again-today/",{"id":274,"title":90,"source":275,"logo":36,"time":92},473489,"https://www.wkyc.com/article/syndication/associatedpress/immunitybio-q4-earnings-snapshot/616-dd910b23-4421-46e4-b3b7-8521913017a3",{"id":277,"title":278,"source":279,"logo":20,"time":92},471223,"ImmunityBio Shares Surge On 700% Revenue Growth Driven By Anktiva - ImmunityBio (NASDAQ:IBRX)","https://www.benzinga.com/markets/earnings/26/02/50790581/immunitybio-explodes-to-near-52-week-high-as-bladder-cancer-drug-anktiva-drives-massive-700-revenue-growth",{"id":281,"title":282,"source":283,"logo":5,"time":92},473488,"ImmunityBio Shares Hit Three-Year High After 4Q Revenue Beats Expectations","https://news.futunn.com/en/post/69127530/immunitybio-shares-hit-three-year-high-after-4q-revenue-beats","#f361a9ff","#f361a94d",1772011858509]